Edesa Biotech (EDSA) Competitors $2.13 +0.09 (+4.41%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$2.13 0.00 (0.00%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. VTGN, ANL, ZIVO, GNTA, SNTI, CUE, PMVP, CNTB, MGX, and IFRXShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include VistaGen Therapeutics (VTGN), Adlai Nortye (ANL), ZIVO Bioscience (ZIVO), Genenta Science (GNTA), Senti Biosciences (SNTI), Cue Biopharma (CUE), PMV Pharmaceuticals (PMVP), Connect Biopharma (CNTB), Metagenomi (MGX), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors VistaGen Therapeutics Adlai Nortye ZIVO Bioscience Genenta Science Senti Biosciences Cue Biopharma PMV Pharmaceuticals Connect Biopharma Metagenomi InflaRx Edesa Biotech (NASDAQ:EDSA) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Do institutionals and insiders have more ownership in EDSA or VTGN? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by company insiders. Comparatively, 1.3% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is EDSA or VTGN more profitable? Edesa Biotech has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -6,777.08%. VistaGen Therapeutics' return on equity of -58.88% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -187.01% -78.72% VistaGen Therapeutics -6,777.08%-58.88%-52.38% Which has stronger valuation and earnings, EDSA or VTGN? Edesa Biotech has higher earnings, but lower revenue than VistaGen Therapeutics. Edesa Biotech is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$6.17M-$1.59-1.34VistaGen Therapeutics$486K121.49-$51.42M-$1.66-1.22 Does the media refer more to EDSA or VTGN? In the previous week, VistaGen Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for VistaGen Therapeutics and 0 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 equaled VistaGen Therapeutics'average media sentiment score. Company Overall Sentiment Edesa Biotech Neutral VistaGen Therapeutics Neutral Which has more volatility & risk, EDSA or VTGN? Edesa Biotech has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Do analysts rate EDSA or VTGN? Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 134.74%. Given Edesa Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Edesa Biotech is more favorable than VistaGen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVistaGen Therapeutics beats Edesa Biotech on 8 of the 15 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.61M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-1.3421.5627.6620.25Price / SalesN/A283.36423.00177.43Price / CashN/A42.7336.8958.10Price / Book3.497.518.035.67Net Income-$6.17M-$55.14M$3.18B$249.21M7 Day Performance3.90%4.61%2.93%3.28%1 Month Performance16.39%0.90%1.72%3.95%1 Year Performance-50.43%5.40%34.39%20.98% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech1.0473 of 5 stars$2.13+4.4%$5.00+134.7%-51.5%$14.61MN/A-1.3420VTGNVistaGen Therapeutics1.5794 of 5 stars$2.00+1.5%N/A-40.4%$57.44M$490K-1.2040ANLAdlai Nortye1.8208 of 5 stars$1.47-5.2%$9.00+512.2%-52.5%$57.20M$5M0.00127ZIVOZIVO BioscienceN/A$14.91flatN/A+41.1%$56.85M$15.85K-3.0610GNTAGenenta Science1.8705 of 5 stars$3.05-1.6%$25.00+719.7%+38.7%$56.70MN/A0.007SNTISenti Biosciences2.6993 of 5 stars$2.11-2.3%$8.50+302.8%-32.3%$56.33M$2.56M-0.194CUECue Biopharma4.0977 of 5 stars$0.68-7.9%$3.00+339.7%-28.3%$55.83M$7.99M-1.0260News CoveragePMVPPMV Pharmaceuticals3.0659 of 5 stars$1.06-0.9%$5.50+418.9%-19.3%$55.59MN/A-0.9050News CoveragePositive NewsCNTBConnect Biopharma3.3285 of 5 stars$0.98-2.0%$7.00+614.3%-14.7%$55.56M$26.03M0.00110News CoveragePositive NewsHigh Trading VolumeMGXMetagenomi1.7793 of 5 stars$1.48+1.4%$13.00+778.4%-60.2%$54.58M$52.29M-0.70236Positive NewsGap UpIFRXInflaRx2.6877 of 5 stars$0.79-2.2%$6.60+735.4%-50.9%$54.23M$180K-0.9660News Coverage Related Companies and Tools Related Companies VTGN Competitors ANL Competitors ZIVO Competitors GNTA Competitors SNTI Competitors CUE Competitors PMVP Competitors CNTB Competitors MGX Competitors IFRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
